Skip to main content
Clinical Trials/NL-OMON42740
NL-OMON42740
Completed
Phase 2

MERIT Study - Mistral Percutaneous Mitral Valve Repair FIM Study - MERIT-FIM

Mitralix Ltd.0 sites4 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
heart valve disorder
Sponsor
Mitralix Ltd.
Enrollment
4
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subject has given signed study Informed Consent for participation prior to procedure.
  • \* Subject is \* 18 years of age or legal age in host country
  • \* Subject is willing and able to comply with all required follow\-up evaluations
  • \* Genders eligible for the study: Both genders
  • \* Subject has functional MR of grade 3\+ or more
  • \* Subject has left ventricular ejection fraction (LVEF) \>20 % and \< 40%.
  • \* No contraindications to trans\-septal puncture
  • \* Subject is of functional class 3 or more (NYHA)
  • \- The subject is high risk to undergo MV surgery as assessed and consented by a cardiac surgeon and an intervention cardiologist at the site (center heart team), and according to ESC/EACTS guidelines on the management of valvular heart disease (including minimum STS score\>4%) or subject voluntarily and consciously refuses surgery
  • \* Subject is excluded from other standard of care procedures as determined by center heart team.

Exclusion Criteria

  • \* Mitral Stenosis \* moderate
  • \* Aortic Stenosis/Insufficiency \> moderate
  • \* Subvalvular calcification or calcification of the chordae.
  • \* Subject has a prosthesis valve in the mitral/aortic position
  • \* Subject has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months.
  • \* Subject has a history of a myocardial infarction (MI) in the past 3 months
  • \* Subject refuses blood transfusion or surgical valve replacement.
  • \* Subject has had a percutaneous interventional or other invasive cardiac or peripheral procedure \* 7 days of the index procedure
  • \* Subject has a history of, or has active endocarditis
  • \* Subject has echocardiographic evidence of intra\-cardiac mass, thrombus, vegetation or soft\-mobile deposits

Outcomes

Primary Outcomes

Not specified

Similar Trials